Disfiguring Hidradenitis Suppurativa of the Face

Capasso, Gianmarco; Fabbrocini, Gabriella; Marasca, Claudio

doi:10.1159/000518433

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence is estimated to be 0.40% [2], with peak age between 30 and 40 years, and an incidence of 3:1 in female [1,2]. Patients with HS suffer a significant reduction in quality of life (QoL) with increased risk of depression, anxiety, sexual dysfunction, and low self-esteem [1,3]. The management of HS has expanded significantly over the past few years, and this includes lifestyle changes, topical therapies, systemic therapies, and surgical therapies [4].…”

Section: Introductionmentioning

confidence: 99%

Certolizumab on treating hidradenitis suppurativa: a brief report

Shadid

Alobaida²,

Binamer³

2022

Dermatol Reports

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS), is a chronic inflammatory skin condition that affects apocrine gland-bearing skin. The management of HS with biologics has expanded significantly over the past few years. Certolizumab pegol (CZP) is a pegylated (polyethylene glycol) antigen-binding fragment (Fab) of a recombinant humanized anti-TNF-α monoclonal antibody, which is approved for psoriasis, rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease. In recent years many reports have been merging on the use of Certolizumab in treating Hidradenitis suppurativa. Methods: The electronic database MEDLINE was searched through PubMed in February 2022 using the following search terms: Certolizumab "[All Fields] OR "certolizumab pegol"[All Fields] AND "Hidradenitis suppurativa" [All Fields Results: The search revealed that Certolizumab was used in 6 case reports to treat Hidradenitis suppurativa with a total of 7 patients. Conclusions: There are few cases in the literature discussing the use of certolizumab in HS , all of which, shows a good and promising responses with no reported side effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Certolizumab on treating hidradenitis suppurativa: a brief report

Shadid

Alobaida²,

Binamer³

2022

Dermatol Reports

View full text Add to dashboard Cite

show abstract

Ultrasonography of Facial and Submandibular Hidradenitis Suppurativa and Concomitance With Acne Vulgaris

Wortsman,

Ortiz‐Orellana,

Valderrama

et al. 2024

J of Ultrasound Medicine

View full text Add to dashboard Cite

ObjectivesTo describe the ultrasound characteristics of facial and submandibular hidradenitis suppurativa (HS) and detect acne vulgaris (AV) concomitance in these cases.MethodsWe performed a retrospective study of the ultrasound images of patients with facial HS who had been clinically evaluated by dermatologists. The reported ultrasound diagnostic criteria, severity (mSOS‐HS), and activity (US‐HAS) staging of HS were used to categorize the patients. The finding of fragments of hair tracts within the key lesions (dilated hair follicles, pseudocysts, fluid collections, and tunnels) was considered a pivotal sign to discriminate HS from AV. Demographic and morphological analysis of the images were considered.ResultsThirty‐three patients met the criteria (78.8% male/21.2% female). Of these, the mSOS‐ HS scoring was stage I in 51.5%, stage II in 27.3%, and stage III in 21.2%. Dilation of the hair follicles and the presence of pseudocysts, fluid collections, and tunnels were detected in the HS cases; 63.1% of pseudocysts, 62.4% of tunnels, and 46.2% of fluid collections contained fragments of hair tracts. In all HS cases, there was a key lesion(s) with fragments of hair tracts. Four (12.1%) patients showed concomitant facial HS and acne ultrasound lesions. The acne lesions were pseudocysts without inner hair tract fragments in all cases, and the SOS‐Acne scoring was stage II for all of them.ConclusionFacial HS can be detected on ultrasound and shows a morphology similar to that of HS in other corporal regions. In some cases, facial HS could be concomitant with AV. The subclinical ultrasonographic information can support a better management of these cases.

show abstract